![Rathmell steps down at NCI as Trump team considers candidates to replace her Wafik El-Deiry, Harvey Risch have been interviewed](https://cdn.cancerletter.com/media/2025/01/17165342/51-02-4x3-1.jpg)
![Rathmell steps down at NCI as Trump team considers candidates to replace her Wafik El-Deiry, Harvey Risch have been interviewed](https://cdn.cancerletter.com/media/2025/01/17165342/51-02-4x3-1.jpg)
Cover Story
White House
W. Kimryn Rathmell has stepped down as NCI director, opting to hand her resignation to the Biden administration over facing the uncertainties that Trump and his team are expected to usher in starting next week.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- Preparing to take care of each other in ways we never imagined
- 20 years of EGFR research: Ramalingam, Carbone, Politi, Jänne, Govindan reflect
- Federal judge blocks Trump administration’s move to limit indirect costs to 15% for NIH-funded institutions
The move could gut academic cancer research - From the chairs of ECOG-ACRIN: A perspective on indirect costs
- What Trump’s pick of RFK Jr. means for cancer: Epidemics, HPV, stunted research
Former FDA Commissioner Scott Gottlieb expresses “deep concerns” - On a new podcast, VCU’s Winn and City of Hope’s Carpten discuss the mission—and the future—of cancer centers
The Cancer Letter’s new podcast offers insight into cancer policy in a landscape of uncertainty